Skip to main content
. 2013 Jun 3;8(6):e65150. doi: 10.1371/journal.pone.0065150

Figure 8. Reversal of 1-MeA-induced GJIC dysregulation using a p38 MAPK inhibitor.

Figure 8

(A) U0126 (20 µM) and FR180204 (5 µM) were used to inhibit MEK or ERK1/2, respectively, prior to exposure to 1-MeA for 30 min. SL/DT assays were then done following 1-MeA treatment. TPA was also used as a positive control. Cntl, acetonitrile control; 1-MeA, 1-methylanthracene (75 µM, 30 min); U0126 alone (20 µM, 1 h prior); U0126+1-MeA, U0126 prior to incubation with 1-MeA; TPA (50 nM, 1 h), TPA alone; U0126+ TPA, U0126 prior to incubation with TPA; FR, FR180204 alone (5 µM, 1 h prior); FR +1-MeA, FR180204 prior to incubation with 1-MeA. Mean ± SEM presented with n = 3 per study, replicated 3 times. *p<0.05 compared to control;+p<0.05 compared to TPA treated cells. (B) SB203580 (2.5, 5 µM) was used to inhibit p38 1 h prior to exposure to 1-MeA for 30 min. SL/DT assays were then done following 1-MeA treatment. SB, SB203580 (2.5 or 5 µM, 1 h); SB +1-MeA, SB203580 prior to incubation with 1-MeA. *p<0.05 compared to control; +p<0.05 compared to 1-MeA treated cells.